Atherosclerosis and cardiovascular events: Aspirin for primary prevention
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2009 May 30;373(9678):1849-60 Meta-Analysis
IN atherosclerosis, coronary disease, stroke, ischemic, cardiovascular death The Use of
aspirin
As Prevention, Primary
Is better Than
placebo
To reduce, both as primary or secondary prevention, serious cardiovascular events but increasing major bleeding. Benefit for primary prevention was limited: 0.51% events aspirin VS 0.57% placebo, 0.10% major bleedings aspirin VS 0.07% placebo
Ann Intern Med. 2009 Mar 17;150(6):405-10 Systematic Review
IN atherosclerosis, coronary disease, stroke, ischemic, cardiovascular death The Use of
aspirin
As Prevention, Primary
Is better Than
placebo
To reduce cardiovascular events (myocardial infarction in men and strokes in women) but not cardiovascular death or overall mortality. Aspirin use increases serious bleeding events.